David Ochoa
@d0choa
Drug discovery | Computational Biology | Human Disease Genetics | ML | Cloud computing - @opentargets - @emblebi
Great chat with @patrick_j_short on finding new drug targets by leveraging human genetic information in a public-private partnership. Thanks to @sanogenetics
Episode 112 of The Genetics Podcast is live! 🚀 This week, we sit down with @d0choa, Platform Coordinator @OpenTargets, to discuss how their platform is enabling game-changing collaboration between academic research & big pharma. Listen here 👇 pod.fo/e/204ce7
Thrilled to see our work on murine oesophageal #Epithelioids published in @NatureGenet, after many years of hard work alongside @AlbertHerms during our postdoc at Phil Jones' lab @Sangerinstitute and built on the foundational work by @MariaPAlcolea nature.com/articles/s4158…
Deploy your own Open Targets Platform in your environment of choice! The latest new contribution to life sciences by the Open Targets Team, that will open the doors to improved reproducibility, collaborations, prototyping, outreach and training activities
🏗️ Want to tinker with the Open Targets Platform to add your own data or tools? Need to check past versions of the Platform? Introducing the Standalone Deployment tool, which allows you to easily deploy any Platform release since March 2023 on your local machine
The @OpenTargets Platform Spring 🌼 release brings a step-change in how we address common disease genetics. We included the results of a large-scale analysis on GWAS and functional genomics studies to inform target selection further 🧬👩💻 blog.opentargets.org/a-step-change-…
Job alert 🚨: join us for a post-doc in beautiful Cambridgeshire !
Postdoc Opportunity. Join the Saez Rodriguez group! Develop computational methods to explore cellular organization & disease mechanisms using multi-omic data. #Postdoc embl.org/jobs/position/…
Join the Club! 🤝 A new study characterises types of Open Science Partnerships, featuring Open Targets as an example of “The Club” This research suggests how OSPs can best be designed for their goals, and provides a framework to understand their impact nature.com/articles/s4159…
Why do clinical trials stop? Researchers from @OpenTargets and EMBL-EBI have developed a machine learning model to analyse clinical trial data. They found a correlation to suggest that trials less supported by genetic evidence are more likely to fail. ebi.ac.uk/about/news/res…
Genetic evidence halves the odds of early clinical trial stoppage 🧬💊 Published today in @NatureGenet, @lesya_rzvvsk trained a machine learning classifier to analyse the free-text reasons explaining why 28,842 clinical trials stopped 3 key points: nature.com/articles/s4158…
Open Targets Platform summer 🌻 release is out with enhanced data and improved therapeutic hypothesis-building capabilities. We continue our sustained effort to connect the necessary dots and understand the risks/benefits of early drug discovery decision-making.
🚨 Open Targets Platform 24.06 has been released!